1.4003.45% ( -0.050 )
Delay Closed: Nov 18, 16:08:04Valuation
Current ValuationThe current P/E ratio is -3.15, above the reasonable range, cheaper than 4.21% of the time in the past 1 years, and the industry ranks 31/78, the industry Median -4.60.
-3.15xP/E
HK$1.40Stock price
HK$-0.44Earnings per share
-3.15xP/E
Stock priceHK$1.40Earnings per shareHK$-0.44
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.31x
- Typical range
- -6.59x–-3.91x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0146292438584
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -49.87x | 66.46% | HK$55.53B |
09688HKZAI LAB | -14.45x | 17.69% | HK$22.49B |
01877HKJUNSHI BIO | -31.10x | 83.59% | HK$14.29B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
02616HKCSTONE PHARMA-B | -19.51x | 1.09% | HK$9.41B |
06855HKASCENTAGE | -5.50x | 19.15% | HK$9.31B |
01952HKEVEREST MED | -139.62x | 326.79% | HK$8.67B |
07666HKMETIS TECHBIO-P | -21.08x | 96.67% | HK$8.58B |
09606HKDUALITYBIO-B | -5.01x | 85.35% | HK$8.29B |
02493HKMABWELL-B | -6.45x | -- | HK$7.89B |
02595HKGENFLEET-B | -4.95x | 66.07% | HK$7.50B |
06938HKRIBOLIFE-B | -34.03x | 29.56% | HK$6.65B |
02335HKMICOT PHARMA-B | -15.02x | 37.52% | HK$6.30B |
09887HKLEADS BIOLABS-B | -19.85x | 3.57% | HK$6.10B |
02171HKCARSGEN-B | -58.45x | 52.33% | HK$6.00B |
09966HKALPHAMAB-B | -25.36x | -- | HK$5.14B |
00775HKCKLIFE SCIENCES | -75.02x | -- | HK$4.85B |
01672HKASCLETIS-B | -6.75x | 78.53% | HK$4.60B |
02256HKABBISKO-B | -8.40x | 814.43% | HK$4.51B |
01779HKLONGBIO-B | -15.75x | -- | HK$3.92B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
